Yardley DA, Liggett W, Mainwaring M, Castrellon A, et al. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clin Breast Cancer 2019 Jun 26. pii: S1526-8209(19)30164.
PMID: 31932237